Ligand Pharmaceuticals Incorporated Stock News

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) CEO John L. Higgins sold 3,000 shares of the stock in a transaction on Friday, November 12th. The stock was sold at an average price of $160.50, for a total transaction of $481,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through []

Ligand (LGND) reports encouraging third-quarter 2021 numbers by beating estimates on both counts.

Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q3 2021 Results - Earnings Call Transcript

Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

AZRX, GHL, HEES, LGND, and POLY have been added to the Zacks Rank #5 (Strong Sell) List on August 5, 2021.

Ligand (LGND) reports encouraging second-quarter 2021 numbers by beating estimates on both counts.

Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q2 2021 Results - Earnings Call Transcript

Ligand (LGND) delivered earnings and revenue surprises of 12.41% and 15.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

PALO ALTO, Calif., July 28, 2021 /PRNewswire/ -- Landing AI™ announced today a software licensing agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to incorporate LandingLens™ into

Ligand helps other biopharma drug developers with its various platforms.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND #earnings--Ligand to Report Second Quarter Financial Results on July 29, 2021

Ligand (LGND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t

NANJING, China and SAN DIEGO, June 2, 2021 /PRNewswire/ -- GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)

Ligand (LGND) reports mixed first-quarter 2021 numbers with earnings beating estimates but revenues missing the same. Stock down.